Wells Fargo Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Wells Fargo downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Outperform to Market Perform.
Shares of Vitae Pharmaceuticals closed at $20.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades ARIAD Pharmaceuticals (ARIA) to Underweight
- Cowen Downgrades AT&T (T) to Market Perform
- UPDATE: Stifel Downgrades SL Green Realty (SLG) to Hold
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesWells Fargo
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!